IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd (NASDAQ:ICCM) saw a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 598,100 shares, a drop of 22.7% from the February 13th total of 773,300 shares. Based on an average daily trading volume, of 385,300 shares, the days-to-cover ratio is presently 1.6 days. Approximately 2.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a research note on Wednesday, November 27th.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd increased its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 123.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,866 shares of the company’s stock after acquiring an additional 32,555 shares during the quarter. XTX Topco Ltd owned about 0.11% of IceCure Medical worth $65,000 as of its most recent filing with the SEC. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Stock Performance

Shares of NASDAQ ICCM traded up $0.08 during mid-day trading on Monday, reaching $1.50. 357,931 shares of the company were exchanged, compared to its average volume of 510,771. The company’s 50-day simple moving average is $1.31 and its 200-day simple moving average is $0.95. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $82.98 million, a P/E ratio of -5.16 and a beta of 0.37. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.66.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.